Background
Acute myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Anemia frequently complicates acute MI, necessitating decisions regarding red blood cell (RBC) transfusion. The MINT trial (Myocardial Ischemia and Transfusion), involving 3,504 patients with MI and hemoglobin levels ≤10 g/dL, compared liberal (maintaining hemoglobin ≥10 g/dL) versus restrictive (maintaining hemoglobin ≥8 g/dL) RBC transfusion strategies. Initial findings suggested that liberal transfusion reduced the composite risk of 30-day death or recurrent MI. However, the impact of transfusion strategy specifically in patients undergoing revascularization (percutaneous coronary intervention or coronary artery bypass grafting) during the index hospitalization remained unclear. This subgroup analysis aimed to address that clinical uncertainty, enhancing guidance on transfusion in this high-risk population.
